News

Teva Pharmaceutical Industries Ltd., the company behind multiple sclerosis drug COPAXONE® (glatiramer acetate injection), has been pursuing the US Food and Drug Administration‘s decision against approving a generic version of the drug, by Mylan, Inc. Teva’s petition has been turned down several times,…

A recent study entitled “STAT5 programs a distinct subset of GM-CSF-producing T helper cells that is essential for autoimmune neuroinflammation” describes a new subset of T helper immune cells – TH-GM – that express a particular cytokine profile with implications in therapeutics for multiple sclerosis. The study was…

Luoxis Diagnostics, Inc. recently presented three clinical and preclinical findings that feature the company’s proprietary RedoxSYS™ Diagnostic System as a comprehensive, groundbreaking tool for research capable of assessing a patient’s oxidation-reduction potential (ORP) in the event of injury, illness, or stress. The findings were presented as peer-reviewed posters during the recently concluded …

The US Food and Drug Administration has just issued a report warning the general public and healthcare providers dealing with multiple sclerosis that one of the leading medications for the disease, Tecfidera (dimethyl fumarate), has been identified a possible factor in the death of an MS patient,…

With 100,000 Canadians living with Multiple Sclerosis (MS), and three people newly diagnosed every day, Canada has one of the highest prevalence rates for the disease in the world. Most people are diagnosed with relapsing MS in their twenties and thirties, and MS is the most common neurological disease affecting…

Researchers from the National University of Singapore have found a new type of immune cell that could aid in the development of treatments for multiple sclerosis (MS). The study was published on November 21 in the journal Cell Research entitled, “STAT5 programs a distinct subset of GM-CSF-producing T helper…

Lexington, MA-based biopharmaceutical company Xenetic Biosciences, Inc. has just announced its new license partner Pharmsynthez has completed dosing in its ongoing Phase 2 clinical trial with pipeline product MyeloXen™ for relapsing remitting and secondary progressive (SPMS) multiple sclerosis. The MyeloXen trial is currently underway in Russia with…

The Cognitive Rehabilitation for Attention and Memory trial (CRAMMS), a major study to be conducted on patients suffering from multiple sclerosis, was recently awarded £1,167,000 ($1,828,000) by the British National Health Service (NHS), through its Health Technology Assessment (HTA) Program. The study, which is expected to be the largest trial of its…

The Alliance for Continuing Education in the Health Professions, an international membership association of healthcare education professionals, has just selected the winner for the 2015 Outstanding CE Enduring Material by the Alliance for Continuing Education in the Health Professions. The winner is a joint CE activity entitled, “Confronting Current Challenges…

The Alliance for Children’s Therapeutics recently announced its plans to broaden its scope of research programs to include several diseases, namely, inflammatory bowel disease (IBD), asthma, and multiple sclerosis (MS) — a progressive, neurodegenerative disease that is estimated to affect 300,000…

The Treat Me Right campaign from the MS Society in the UK was recently shortlisted for this year’s voluntary sector campaign Public Affairs Award. The campaign was launched in April 2014 during MS Week to raise awareness for the importance of providing the right treatment at the right moment…

In a poster session at the Annual meeting of the Society for Neuroscience in Washington, ENDECE Neural presented pre-clinical results showing their lead drug – NDC-1308 – induces remyelination in mouse models of demyelination disease, such as Multiple Sclerosis. Loss of myelin is the main characteristic of a group…

For those with Multiple Sclerosis, the progressive manner in which the disease slowly deteriorates motor function, balance, and coordination can make home maintenance an impossibility. Add to this the well-documented issues that MS patients have with finding and keeping jobs and very quickly the cost and effort to maintain…

Unconventional medical approaches and lifestyle changes may help patients suffering from multiple sclerosis (MS) improve their health and well-being, according to Allen Bowling, MD, PhD, an internationally recognized neurologist and specialist in alternative medicine. The physician has designed a seven-step method based on his expertise, which is presented on his…

Cambridge, Massachusetts based Genzyme announced Friday that the U.S. Food and Drug Administration (FDA) has approved the company’s new drug Lemtrada (alemtuzumab) for treatment of people with relapsing forms of multiple sclerosis, which includes people who experience periodic MS attacks, such as those who have relapsing-remitting MS or secondary-progressive…

Upper limb spasticity and lower leg cramps and spasms, two conditions that affect patients with multiple sclerosis, are being treated in separate clinical trials with results from both showing positive benefits. Dysport (abobotulinumtoxinA), from Ipsen Biopharmaceuticals, Inc., and transient receptor potential (TRP) activators, from…

Teva Pharmaceutical Industries Ltd., the company that developed the injectable multiple sclerosis treatment Copaxone (Glatiramer acetate),  has announced their pursuit of regulatory approval in Japan. This development comes a year after signing an agreement with Takeda Pharmaceutical Co. Ltd. According to a…

Highmark Blue Cross Blue Shield is trying to assess the possibility of predicting good and bad days for people suffering with multiple sclerosis (MS) and help them to achieve a higher quality of life. The four-week pilot program enrolled almost 100 participants that wore a body sensor patch,…

Oceans of Hope, a 67-foot sail yacht currently docked at North Cove Marina, New York, is on a round-the-world voyage to become the first ship to ever circumnavigate with a crew of people who have Multiple Sclerosis. The voyage, initiated by Sailing Sclerosis Foundation, set sail from Copenhagen, Denmark…

New Zealand and Australia-based Innate Immunotherapeutics Limited, a medical biotechnology company with offices in Sydney and Auckland, has issued an update regarding its Phase 2B trial for secondary progressive multiple sclerosis (SPMS) and other recent activities. The Phase 2B MIS416 trial Patient dosing with MIS416…

One of the country’s leading non-profit multiple sclerosis organizations, the Multiple Sclerosis Association of America (MSAA), has just launched a new patient support website called, My MS Journey. It is a comprehensive online resource designed to answer the specific and varied needs of MS patients, whether they have…

In a study entitled “Developmental endothelial locus-1 is a homeostatic factor in the central nervous system limiting neuroinflammation and demyelination” the authors report to have found a new protein, Del-1, that reduces the severity of multiple sclerosis disease in a mouse model of the disease. The…

What may be overlooked in relating to and caring for patients with multiple sclerosis is the fact that the neurodegenerative disease sometimes affects a person’s ability to properly convey and perceive emotion. According to the National Multiple Sclerosis Society (NMSS), while there is not…

A team of researchers at the Tel Aviv University report the role of obesity as a major risk factor triggering and maintaining autoimmune diseases, such as Crohn’s Disease and multiple sclerosis. The study was published in Autoimmunity Reviews. In autoimmune diseases, the immune system reacts against the body…

Patients who suffer from progressive conditions, such as multiple sclerosis (MS), are submitted to unnecessary evaluations for disability benefits and often denied the full payment of their out-of-work benefits or deemed as fit to work when they are in fact not able. This new perspective was highlighted by a…

Photo From University of Alberta The company behind FDA-approved multiple sclerosis drug AVONEX® (Interferon beta-1a), Biogen Idec, together with the government of the province of Alberta, has…

Drug manufacturers Teva Pharmaceutical Industries Ltd. and Active Biotech announced that they expanding the ongoing clinical research program for the study of laquinimod, a potential treatment for primary progressive multiple sclerosis (PPMS), as the companies are now initiating the ARPEGGIO trial. In addition, Teva has also announced…

Sanofi subsidiary and rare disease treatment specialist Genzyme has just announced the successful enrollment of the first participant in their multicenter Phase II clinical trial for the company’s pipeline intravenous drug for relapsing-remitting multiple sclerosis (RRMS), vatelizumab. This novel drug is composed of humanized monoclonal antibodies that specifically target…

The National Multiple Sclerosis Society recently awarded MS researcher Lauren Strober, PhD from the Kessler Foundation, a three-year grant for her investigational research, totaling $457,921. The funding is part of a multi-site study that will be conducted by the investigator to understand the influence that having…

A study entitled “Longitudinal Follow-up of a Cohort of Patients with Incidental Abnormal Magnetic Resonance Imaging Findings at Presentation and Their Risk of Developing Multiple Sclerosis” published in the International Journal of MS Care reports that asymptomatic patients accompanied by Magnetic Resonance Images suggestive of…